Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

71.96 +0.82 (+1.16%)
Streaming Delayed Price Updated: 1:54 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biomarin Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits. 
Via Benzinga
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
The companies could soon face off in the growth treatment market for children with a genetic disorder. 
Via Investor's Business Daily
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock which is not overvalued. 
Via Chartmill
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth. 
Via Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. 
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Aug. 19-23, 2024. 
Via Talk Markets
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable. 
Via Chartmill
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven... 
Via Benzinga
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Via Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Via Benzinga
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable. 
Via Chartmill
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
KKR and GoDaddy also will join before the open on June 24. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.